SOHM Announces Exclusive Private Label Manufacturing Agreement for Generic Pharmaceutical Products
* Reuters is not responsible for the content in this press release.
BUENA PARK, CA, Jan 12 (MARKET WIRE) --
SOHM, Inc. (PINKSHEETS: SHMN), a generic pharmaceutical manufacturer that
produces and markets generic drugs covering all major treatment
categories, today announced an exclusive private label and development
agreement with an India-based generic pharmaceutical manufacturer. The
two companies have formed a global platform for the introduction of the
SOHM brand of generic medicines into the African, Latin American, and
Southeast Asian markets. Generic pharmaceuticals sourced through this
agreement will be labeled under the SOHM brand and will be distributed
directly under SOHM's manufacturing license in India. The agreement will
enable both companies to gain additional, global experience in some of
the fastest growing emerging marketplaces for generic pharmaceuticals.
Drug and Pharmaceutical product categories included in the exclusive
distribution agreement include antiarthritic/analgesic agents, anticancer
agents, antifungal agents, anti-infective agents, cardiovascular agents,
central nervous system agents, dermatological agents, gastrointestinal
agents, respiratory agents, biotechnology, hormones, and other generic
drugs including anesthetics, antidiabetic agents, antiemetics,
dermatologicals, immunosuppressive agents, ophthalmic drugs, and
treatments for benign prostatic hyperplasia.
"This exclusive agreement makes SOHM a truly international brand. We are
combining our strengths and competencies to deliver SOHM branded drugs to
the fastest growing pharmaceutical medicine markets in the world," stated
Vice President for Corporate Strategy at SOHM, Inc. Shailesh Shah.
About SOHM, Inc.
SOHM, Inc. is a generic pharmaceutical manufacturer that produces and
markets generic drugs covering all major treatment categories. Global
headquarters is located in North America with manufacturing sites in
India. Generic pharmaceuticals are exported globally with a focus on
distribution in emerging markets in Africa, Latin America, and Southeast
Asia. www.sohm.com
Safe Harbor Statement
This press release contains statements, which may constitute
"forward-looking statements" within the meaning of the Securities Act of
1933 and the Securities Exchange Act of 1934, as amended by the Private
Securities Litigation Reform Act of 1995. Those statements include
statements regarding the intent, belief or current expectations of SOHM,
Inc., and members of their management as well as the assumptions on which
such statements are based. Prospective investors are cautioned that any
such forward-looking statements are not guarantees of future performance
and involve risks and uncertainties, and that actual results may differ
materially from those contemplated by such forward-looking statements.
Important factors currently known to management that could cause actual
results to differ materially from those in forward-statements include
fluctuation of operating results, the ability to compete successfully and
the ability to complete before-mentioned transactions. The company
undertakes no obligation to update or revise forward-looking statements to
reflect changed assumptions, the statements to reflect changed
assumptions, the occurrence of unanticipated events or changes to future
operating results.
For more information, please contact:
SOHM, Inc.
Investor Relations
(714) 522-6700
Email Contact
Copyright 2009, Market Wire, All rights reserved.
-0-
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.



Follow Reuters